Thompson Davis & CO. Inc. raised its position in shares of Voyager Therapeutics Inc (NASDAQ:VYGR) by 67.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,485 shares of the company’s stock after buying an additional 3,021 shares during the quarter. Thompson Davis & CO. Inc.’s holdings in Voyager Therapeutics were worth $124,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Rhumbline Advisers lifted its stake in Voyager Therapeutics by 34.7% during the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after buying an additional 4,144 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Voyager Therapeutics by 8.9% during the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after buying an additional 1,399 shares in the last quarter. Teachers Advisors LLC lifted its stake in Voyager Therapeutics by 24.7% during the second quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after buying an additional 5,081 shares in the last quarter. California State Teachers Retirement System lifted its stake in Voyager Therapeutics by 8.4% during the second quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after buying an additional 2,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in Voyager Therapeutics by 0.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock valued at $261,000 after buying an additional 114 shares in the last quarter. 36.18% of the stock is owned by institutional investors.

In other news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $13.26, for a total value of $72,797.40. Following the transaction, the insider now owns 16,473 shares in the company, valued at approximately $218,431.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 14,610 shares of company stock worth $207,158 in the last quarter. 8.00% of the stock is owned by corporate insiders.

A number of analysts have commented on the stock. Zacks Investment Research raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. Stifel Nicolaus reaffirmed a “buy” rating and set a $31.00 price objective (up from $20.00) on shares of Voyager Therapeutics in a research note on Monday, October 23rd. Canaccord Genuity reaffirmed a “buy” rating and set a $26.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, January 23rd. Raymond James Financial began coverage on shares of Voyager Therapeutics in a research note on Thursday, October 12th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.90.

Voyager Therapeutics Inc (NASDAQ:VYGR) opened at $18.40 on Tuesday. The firm has a market capitalization of $589.99, a PE ratio of -6.48 and a beta of 4.04. Voyager Therapeutics Inc has a twelve month low of $8.10 and a twelve month high of $25.99.

COPYRIGHT VIOLATION WARNING: “Thompson Davis & CO. Inc. Has $124,000 Holdings in Voyager Therapeutics Inc (VYGR)” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/02/06/thompson-davis-co-inc-has-124000-holdings-in-voyager-therapeutics-inc-vygr.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.